<DOC>
	<DOCNO>NCT01565707</DOCNO>
	<brief_summary>Solifenacin succinate tablet formulation already market treatment symptom overactive bladder adult . For use child adolescent patient new formulation solifenacin develop . This study investigate effect safety solifenacin succinate liquid suspension compare non-active drug ( placebo ) 12-week period . The 2 week prior double blind period single-blind placebo run-in period combination behavioral urotherapy ( Non-interventional diary assist urotherapy consist overactive bladder ( OAB ) information , awareness , instruction , life-style advice documentation void habit symptom OAB ) , follow 12 week daily treatment period . The study also investigate well solifenacin succinate suspension taken-up body long stay body time .</brief_summary>
	<brief_title>A Study Investigate How Effective Safe Solifenacin Succinate Suspension Treating Children/Adolescents Aged 5 Less Than 18 Years With Symptoms Overactive Bladder ( OAB ) Compared Non-active Drug</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Main Written Informed Consent obtain OAB ( symptoms urgency ) accord International Children 's Continence Society ( ICCS ) criterion Daytime incontinence least 4 episode incontinence confirm 7 day participant diary Main Daily void frequency le 5 Extraordinary daytime urinary frequency accord International Children 's Continence Society ( ICCS ) definition Uroflow indicative pathology OAB Maximum void volume ( morning volume exclude ) &gt; expect bladder capacity age [ ( age +1 ) x 30 ] ml maximum voided volume ( morning volume exclude ) 390 ml Post Void Residual ( PVR ) &gt; 20 ml Monosymptomatic enuresis Polyuria define &gt; 75 ml/kg/b.w./24 hour Dysfunctional void Congenital anomaly affect low urinary tract function Current constipation Current Urinary Tract Infection ( UTI ) Catheterization within 2 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Solifenacin succinate suspension</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Overactive bladder ( OAB )</keyword>
</DOC>